Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Human umbilical cord mesenchymal stem cells(Beijing Baolai) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Human umbilical cord mesenchymal stem cells(Beijing Baolai): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing de
9 min read
CYT-101(Cyteph) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
CYT-101(Cyteph): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
![[177Lu]-DFC413 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go](https://synapse-static.patsnap.com/strapi-static/Blog_cover_13_1a4cebe3b5.jpg)
9 min read
[177Lu]-DFC413 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
[177Lu]-DFC413: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Abicipar pegol Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Abicipar pegol: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
RP-3 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
RP-3: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ARG-Vx-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
ARG-Vx-001: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
SFR-9216 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
SFR-9216: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
RP-A701 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
RP-A701: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
24-valent pneumococcal conjugate vaccine(Microbial Technology) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
24-valent pneumococcal conjugate vaccine(Microbial Technology): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing
9 min read
mRNA-4200 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
mRNA-4200: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
AV-5124 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
AV-5124: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
B1-1701963 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
B1-1701963: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.